Cognizance Biomarkers

Developing EvoScoreDX, a diagnostic that rapidly and accurately identifies epileptic seizures, yielding improved outcomes at significant cost savings.

  • Stage Prototype Ready
  • Industry Medical Devices and Equipment
  • Location Philadelphia, PA, USA
  • Currency USD
  • Founded July 2012
  • Employees 4
  • Incorporation Type C-corp
  • Website cognizancebio.com

Company Summary

• Revolutionary, blood-based proteomic epileptic seizure diagnostic, offering objective, reliable and actionable results
• Large worldwide addressable markets with significant unmet needs
• Strong diagnostic performance for lifetime patient management
• H1 2021 launch supported by primary research demonstrating 97% physician willingness to prescribe
• Forecasted sales of >$500M in US with limited competition
• Multiple granted patents

Team

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free